Eileen M O'Reilly

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, York, NY 10022, USA
    J Clin Oncol 24:4293-300. 2006
  2. pmc Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?
    Walid Faraj
    Liver Transplantation and Hepatopancreaticobiliary Surgery, Department of General Surgery, American University of Beirut, Cairo Street, Beirut 1107 2020, Lebanon
    World J Surg Oncol 11:131. 2013
  3. doi request reprint Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers
    Eileen M O'Reilly
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer J 18:609-13. 2012
  4. doi request reprint Adjuvant therapy for pancreas adenocarcinoma
    Eileen M O'Reilly
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Surg Oncol 107:78-85. 2013
  5. ncbi request reprint A phase II study of irinotecan in patients with advanced hepatocellular carcinoma
    E M O'Reilly
    Department of Medicine, Solid Tumor Division, GI Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 91:101-5. 2001
  6. ncbi request reprint Adjuvant therapy for pancreas adenocarcinoma: where are we going?
    Eileen M O'Reilly
    Department of Medicine, Gastrointestinal Oncology Service, 1275 York Avenue, Box 324, New York, NY 10065, USA
    Expert Rev Anticancer Ther 11:173-7. 2011
  7. pmc A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)
    Eileen M O'Reilly
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 15:1310-9. 2010
  8. ncbi request reprint Cytotoxic therapy for advanced pancreatic adenocarcinoma
    Eileen M O'Reilly
    Department of Medicine, Gastrointestinal Oncology Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:347-53. 2007
  9. ncbi request reprint Cisplatin and irinotecan in upper gastrointestinal malignancies
    E M O'Reilly
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Oncology (Williston Park) 15:42-5. 2001
  10. doi request reprint New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy
    Maeve A Lowery
    Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
    BioDrugs 25:207-16. 2011

Detail Information

Publications47

  1. ncbi request reprint Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, York, NY 10022, USA
    J Clin Oncol 24:4293-300. 2006
    ..This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients...
  2. pmc Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?
    Walid Faraj
    Liver Transplantation and Hepatopancreaticobiliary Surgery, Department of General Surgery, American University of Beirut, Cairo Street, Beirut 1107 2020, Lebanon
    World J Surg Oncol 11:131. 2013
    ..There are conflicting data regarding the safety of pancreatic resection in older patients. Potentially modifiable perioperative risk factors to improve outcomes in older patients have yet to be determined...
  3. doi request reprint Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers
    Eileen M O'Reilly
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer J 18:609-13. 2012
    ..One advantage to the development of defined guidelines would be greater consistency in the setting of both routine clinical follow-up and follow-up after adjuvant therapy on trial...
  4. doi request reprint Adjuvant therapy for pancreas adenocarcinoma
    Eileen M O'Reilly
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Surg Oncol 107:78-85. 2013
    ..Progress to date has been modest and incremental in the adjuvant setting...
  5. ncbi request reprint A phase II study of irinotecan in patients with advanced hepatocellular carcinoma
    E M O'Reilly
    Department of Medicine, Solid Tumor Division, GI Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 91:101-5. 2001
    ..In a Phase II clinical trial, two academic centers assessed irinotecan, a topoisomerase-1 inhibitor with broad spectrum clinical activity, in patients who had advanced hepatocellular cancer...
  6. ncbi request reprint Adjuvant therapy for pancreas adenocarcinoma: where are we going?
    Eileen M O'Reilly
    Department of Medicine, Gastrointestinal Oncology Service, 1275 York Avenue, Box 324, New York, NY 10065, USA
    Expert Rev Anticancer Ther 11:173-7. 2011
    ....
  7. pmc A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)
    Eileen M O'Reilly
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 15:1310-9. 2010
    ..gov identifier, NCT00397787). The primary endpoint was to determine the disease control rate (DCR) as measured by the Response Evaluation Criteria in Solid Tumors (complete response, partial response [PR], and stable disease) at 6 weeks...
  8. ncbi request reprint Cytotoxic therapy for advanced pancreatic adenocarcinoma
    Eileen M O'Reilly
    Department of Medicine, Gastrointestinal Oncology Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:347-53. 2007
    ..This underscores the major therapeutic hurdles that we have to surmount in this most challenging of human malignancies...
  9. ncbi request reprint Cisplatin and irinotecan in upper gastrointestinal malignancies
    E M O'Reilly
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Oncology (Williston Park) 15:42-5. 2001
    ..Preliminary data on all of these combinations suggest promising activity in upper gastrointestinal malignancies...
  10. doi request reprint New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy
    Maeve A Lowery
    Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
    BioDrugs 25:207-16. 2011
    ..Herein we discuss recent advances in the development of novel therapeutic approaches to PAC, focusing in particular on recent developments in immune and vaccine therapy...
  11. doi request reprint Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Invest 27:402-6. 2009
    ..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
  12. pmc Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy
    Maeve A Lowery
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1714-20. 2011
    ..We present a series of 40 consecutive cases of ACC of the pancreas treated at Memorial Sloan-Kettering Cancer Center, with an emphasis on evaluation of activity of new therapeutic agents...
  13. ncbi request reprint Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    J Clin Oncol 24:4441-7. 2006
    ..A multicenter, randomized, phase III trial comparing exatecan plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer was conducted...
  14. ncbi request reprint Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer
    Sibyl E Anderson
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, New York, USA
    Cancer Invest 21:512-6. 2003
    ..Given the activity of paclitaxel in esophageal cancer, a phase II trial of 96-hour infusion paclitaxel in esophageal cancer was undertaken...
  15. doi request reprint A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients
    Andrew S Epstein
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Palliat Med 16:623-31. 2013
    ..Cardiopulmonary resuscitation (CPR) is an important advance directive (AD) topic in patients with progressive cancer; however such discussions are challenging...
  16. doi request reprint Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Clin Oncol 34:321-5. 2011
    ..The objective of this study was to assess the safety and efficacy of immunizing patients with resected pancreatic cancer with a vaccine targeted against their tumor-specific K-ras mutation...
  17. doi request reprint Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis
    Patrick L Wagner
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Dis Colon Rectum 55:407-15. 2012
    ..At our institution, patients undergoing complete cytoreduction in this setting typically receive multiple cycles of early postoperative intraperitoneal chemotherapy...
  18. pmc Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
    Fidel David Huitzil-Melendez
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:2889-95. 2010
    ..Many staging systems that include both aspects have been developed. It remains unknown, however, which of these systems is optimal for predicting patient survival...
  19. doi request reprint Targeted agents and systemic therapy in hepatocellular carcinoma
    Celina Ang
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Recent Results Cancer Res 190:225-46. 2013
    ..Several pathways are now implicated in hepatocarcinogenesis and agents that target these pathways continue to be developed...
  20. doi request reprint Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review
    Rabih Said
    Staten Island University Hospital, New York, USA
    Eur J Gastroenterol Hepatol 22:246-52. 2010
    ..As the data confers a worse prognosis versus other pancreatic neuroendocrine tumors, the relatively favorable outcome of the two patients reported herein may reflect the impact of multiple therapeutic modalities...
  21. doi request reprint Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer
    Andrew S Epstein
    Department of Medicine, Division of Gastrointestinal Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:3053-61. 2012
    ..Pancreatic cancer-specific thrombosis studies examining the correlation between clinical variables, including thrombosis timing and the impact of thrombosis on survival, have not been reported...
  22. doi request reprint A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Pancreatology 9:404-9. 2009
    ..This phase II study was designed to further define the efficacy and toxicity of this regimen in patients with previously treated PC...
  23. doi request reprint A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma
    Maeve Lowery
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Gastrointest Cancer 42:160-4. 2011
    ..Individuals who carry a germline mutation in the BRCA 1 or 2 genes have an increased lifetime risk of developing pancreatic adenocarcinoma when compared with the general population...
  24. ncbi request reprint What is the optimal treatment of localized pancreatic adenocarcinoma?
    Austin Duffy
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncology (Williston Park) 22:1283-91; discussion 1294, 1296-8. 2008
    ..Going forward, with the expectation of new and improved systemic agents, locoregional tumor control and, hence, chemoradiotherapy are anticipated to have a greater role and impact...
  25. ncbi request reprint Biliary tract cancers: current concepts and controversies
    Gregory D Leonard
    Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, Department of Medicine, 1275 York Avenue, Box 324, New York, New York 10021, USA
    Expert Opin Pharmacother 6:211-23. 2005
    ..Further progress in the management of biliary tract cancer is anticipated using biological therapies and continued research is essential to discover the optimal treatment for this challenging disease...
  26. pmc An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions
    Maeve A Lowery
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1397-402. 2011
    ....
  27. doi request reprint A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States Electronic address
    J Hepatol 60:319-24. 2014
    ..IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study...
  28. doi request reprint Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012
    ..As yet, however, there are no data to support the inclusion of these tumors into general screening guidelines for detecting Lynch syndrome, nor are there data to warrant surveillance for these tumors in patients with Lynch syndrome...
  29. ncbi request reprint Exocrine pancreas cancer and thromboembolic events: a systematic literature review
    Andrew S Epstein
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Natl Compr Canc Netw 10:835-46. 2012
    ....
  30. doi request reprint Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma
    Austin Duffy
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 7:140-3. 2008
    ..He underwent hepatic metastasectomy and was found to have had a complete pathologic response (pCR) to treatment. The literature regarding pCR with chemotherapy in CRC and the implications for further management is discussed herein...
  31. doi request reprint Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor
    Celina Ang
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Gastrointest Cancer 42:165-70. 2011
    ..The workup and management of a carcinoma of unknown primary must consider the patient's clinical presentation, radiologic and pathologic findings, and comorbidities...
  32. doi request reprint Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers
    Fidel David Huitzil-Melendez
    Section of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10022, USA
    Surg Oncol Clin N Am 18:361-79, x. 2009
    ..This article reviews the available evidence to support indications of systemic chemotherapy in the palliative setting and discuss the attempts to study it in the perioperative settings...
  33. ncbi request reprint Selection of patients with hepatocellular carcinoma for sorafenib
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Natl Compr Canc Netw 7:397-403. 2009
    ..This article addresses these questions on the use of sorafenib in HCC, both in the locally advanced and metastatic settings, in addition to the potential future applications and uses of sorafenib...
  34. pmc Hepatocellular carcinoma: molecular biology and therapy
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 33:S79-83. 2006
    ....
  35. doi request reprint Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer
    Elizabeth Smyth
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Gastrointest Cancer 42:46-9. 2011
    ..Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths. Appropriate staging and treatment options relate to the stage of disease and performance status of the patient...
  36. doi request reprint Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
    ..The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial...
  37. ncbi request reprint The impact of new data in the treatment of advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10022, USA
    Curr Oncol Rep 10:199-205. 2008
    ....
  38. ncbi request reprint A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Am J Clin Oncol 28:334-9. 2005
    ..A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma...
  39. doi request reprint Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis
    Austin Duffy
    Deparment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Colorectal Cancer 7:402-5. 2008
    ..Platinum-based chemotherapy resulted in a divergent pathologic response as assessed after colectomy. The diagnosis and classification of mixed endocrine-exocrine tumors of the colon are discussed, along with treatment considerations...
  40. pmc Current management of advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY
    Gastrointest Cancer Res 2:64-70. 2008
    ..The innovative therapeutic outcomes associated with novel targeted therapies illustrates the need for biologic and pharmacokinetic end points to define their optimal doses and therapeutic effects...
  41. doi request reprint Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection
    Itaru Endo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 248:84-96. 2008
    ..This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort...
  42. pmc A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers
    Jordan M Winter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America corrected
    PLoS ONE 7:e40157. 2012
    ..To help researchers sort through the maze of biomarker data, a compendium of ∼2500 published candidate biomarkers in PDA was compiled (PLoS Med, 2009. 6(4) p. e1000046)...
  43. doi request reprint Synchronous epithelial and neuroendocrine cancers of the pancreas: case series of a rare occurrence
    Derek G Power
    Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Colorectal Cancer 10:146-50. 2011
    ..We report 2 cases with a purpose of discussing management strategies, prognosis, and potential etiologies of this rare presentation...
  44. doi request reprint MicroRNA, hypoxic stress and hepatocellular carcinoma: Future directions
    Celina Ang
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Gastroenterol Hepatol 26:1586-8. 2011
    ..See article in J. Gastroenterol. Hepatol. 2011; 26: 1630-1637...
  45. doi request reprint Costs and trends in pancreatic cancer treatment
    Caitriona B O'Neill
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 118:5132-9. 2012
    ....
  46. pmc Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study
    Angelo E Volandes
    General Medicine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 118:4331-8. 2012
    ..The authors tested whether an educational video on the goals of care in advanced cancer (life-prolonging care, basic care, or comfort care) helped patients understand these goals and had an impact on their preferences for resuscitation...
  47. ncbi request reprint Pancreatic cancer: the role of molecular markers in diagnosis and management
    Maeve A Lowery
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Adv Hematol Oncol 9:900-8. 2011
    ..Herein, we discuss the current status of molecular markers in the diagnosis and management of PAC and review potential clinical applications thereof...